direct antithrombins  

     

Select
Display
Trial Studied trt Control trt patientstagsNCTROB Result

atrial fibrillation

dabigatran
RE-LY (110mg), 2009dabigatran 110mgwarfarin standard doseNCT00262600Risk of bias suggesting
PETRO (150mg), 2007dabigatran 150mgwarfarin standard doseExploratory -
RE-LY (150mg), 2009dabigatran 150mgwarfarin standard doseNCT00262600Risk of bias suggesting
ximelagatran
SPORTIF II (ximelagatran vs warfarin standard dose), 2002ximelagatranwarfarin standard doseRisk of bias -
SPORTIF III, 2003ximelagatranwarfarin standard doseRisk of bias suggesting
SPORTIF V, 2005ximelagatranwarfarin standard doseLow risk of bias suggesting

thrombosis prevention

dabigatran
RE-NOVATE (150mg), 2007dabigatran 150mgenoxaparinNCT00168818Low risk of bias negative
RE-NOVATE (220mg), 2007dabigatran 220mgenoxaparinNCT00168818Low risk of bias negative
RE-NOVATE 2dabigatran 220mgenoxaparinNCT00657150Low risk of bias negative
RE-MODEL (150mg), 2007dabigatran 150mgenoxaparin (europe regimen)Low risk of bias negative
RE-MODEL (220mg), 2007dabigatran 220mgenoxaparin (europe regimen)Low risk of bias negative
RE-MOBILIZE (150mg), 2008dabigatran 150mgenoxaparin (US regimen)Low risk of bias negative
RE-MOBILIZE (220mg), 2008dabigatran 220mgenoxaparin (US regimen)Low risk of bias negative
ximelagatran
METHRO I, 2002ximelagatranDalteparinnegative
METHRO II, 2002ximelagatranDalteparinLow risk of bias suggesting
Phase II (Heit), 2001ximelagatranEnoxaparinLow risk of bias negative
Platinum (Colwell), 2003ximelagatranEnoxaparinLow risk of bias negative
METHRO III, 2002ximelagatranEnoxaparinLow risk of bias negative
EXPRESS, 2003ximelagatranEnoxaparinLow risk of bias suggesting